{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:22:19Z","timestamp":1762161739092,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41571-022-00711-4","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T13:05:03Z","timestamp":1668517503000},"page":"5-6","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL"],"prefix":"10.1038","volume":"20","author":[{"given":"Richard T.","family":"Maziarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8409","authenticated-orcid":false,"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"711_CR1","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41409-019-0552-y","volume":"55","author":"ZH Hu","year":"2020","unstructured":"Hu, Z. H., Peter Gale, R. & Zhang, M. J. Direct adjusted survival and cumulative incidence curves for observational studies. Bone Marrow Transplant. 55, 538\u2013543 (2020).","journal-title":"Bone Marrow Transplant."},{"key":"711_CR2","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.bbmt.2015.06.004","volume":"21","author":"N Khera","year":"2015","unstructured":"Khera, N. et al. Comparison of characteristics and outcomes of trial participants and nonparticipants: example of blood and marrow transplant clinical trials network 0201 trial. Biol. Blood Marrow Transplant. 21, 1815\u20131822 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"711_CR3","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145\u20132154 (2022).","journal-title":"Nat. Med."},{"key":"711_CR4","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","volume":"163","author":"MA Brookhart","year":"2006","unstructured":"Brookhart, M. A. et al. Variable selection for propensity score models. Am. J. Epidemiol. 163, 1149\u20131156 (2006).","journal-title":"Am. J. Epidemiol."},{"key":"711_CR5","first-page":"349","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge, W. A. et al. GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140, 349\u2013358 (2022).","journal-title":"Blood"},{"key":"711_CR6","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood.2021014497","volume":"139","author":"J Gauthier","year":"2022","unstructured":"Gauthier, J. et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood 139, 3722\u20133731 (2022).","journal-title":"Blood"},{"key":"711_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","volume":"28","author":"PA Riedell","year":"2022","unstructured":"Riedell, P. A. et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas. Transplant Cell Ther. 28, 669\u2013676 (2022).","journal-title":"Transplant Cell Ther."},{"key":"711_CR8","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole, O. O. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 194, 690\u2013700 (2021).","journal-title":"Br. J. Haematol."},{"key":"711_CR9","unstructured":"NICE. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. nice.org.uk, https:\/\/www.nice.org.uk\/guidance\/ta554 (21 December 2022)."},{"key":"711_CR10","unstructured":"ICER. Leukemia and Lymphoma. icer.org https:\/\/icer.org\/assessment\/leukemia-and-lymphoma-2018 (March 2018)."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00711-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T14:09:31Z","timestamp":1671458971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00711-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1038\/s41571-022-00711-4","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"type":"print","value":"1759-4774"},{"type":"electronic","value":"1759-4782"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"15 November 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.T.M. has acted as a consultant and\/or adviser of Artiva Therapeutics, Bristol-Myers Squibb\/Celgene, CRISPR Therapeutics, Incyte, Kite and Novartis and has received research funding from BMS and Novartis. J.G. has acted as a consultant and\/or adviser of Janssen, Kite Pharma, Legend Biotech and MorphoSys and has received research funding from Angiocrine Bioscience, Celgene (a BMS company), Juno Therapeutics (a BMS company) and Sobi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}